Nigeria, Cameroon, Chad to introduce new meningitis vaccine

"The World Health Organization (WHO) on Friday said that Nigeria, Cameroon and Chad, who are in the 'meningitis belt' stretching across Africa, will this month introduce a new vaccine designed to eliminate a particular strain of the often deadly disease," Afrique en ligne reports (12/10). "Alison Brunier, a spokesperson for WHO, told journalists in Geneva that the three countries plan to vaccinate about 22 million people [among] them, focusing on the highest-risk demographic category -- those aged between one and 29 years" and that "the immunization campaign should be completed within a couple of weeks," the U.N. News Centre writes (12/9).

"A statement made available to PANA in New York stated that the countries will vaccinate millions of their citizens with 'MenAfriVac,' which was created to target Group A meningitis, responsible for millions of cases in sub-Saharan Africa over the past century," Afrique en ligne notes (12/10). "A year ago, Burkina Faso became the first country to conduct a nationwide campaign using MenAfriVac, and, according to Brunier, the campaign would be extended to 19 other countries within the belt (Senegal in the West to Ethiopia in the East) by 2016," Nigeria's Leadership writes (Oluwarotimi, 12/11).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests no need for yellow fever vaccine booster after initial dose